



**PEER-REVIEW REPORT**

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 97702

**Title:** B cell-specific signatures reveal novel immunophenotyping and therapeutic targets for hepatocellular carcinoma

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer’s code:** 08148906

**Position:** Peer Reviewer

**Academic degree:** Md

**Professional title:** Doctor

**Reviewer’s Country/Territory:** Reviewer\_Country

**Author’s Country/Territory:** China

**Manuscript submission date:** 2024-06-05

**Reviewer chosen by:** Yu-Lu Chen

**Reviewer accepted review:** 2024-07-18 06:05

**Reviewer performed review:** 2024-07-18 06:30

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Novelty of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
<b>Creativity or innovation of this manuscript</b>	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

Your research on "B cell-specific signatures reveal novel immunophenotyping and therapeutic targets for hepatocellular carcinoma" presents an interesting and valuable exploration into the role of B cells in hepatocellular carcinoma (HCC). The team's expertise in various medical disciplines, including hepatobiliary and pancreatic surgery, pharmacy, basic medical sciences, and gastrointestinal surgery, provides a strong multidisciplinary foundation for this study. The breadth of your institutional affiliations, ranging from Zhongnan Hospital of Wuhan University, Union Hospital at Tongji Medical College, Nanjing Medical University, The Second Affiliated Hospital of Kunming Medical University, and the Second People's Hospital of Jiaozuo City, suggests a collaborative effort that leverages diverse resources and perspectives. This integrated approach is essential for gaining a comprehensive understanding of the complex interplay between B cells and HCC.



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 97702

**Title:** B cell-specific signatures reveal novel immunophenotyping and therapeutic targets for hepatocellular carcinoma

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 08165500

**Position:** Peer Reviewer

**Academic degree:** Md

**Professional title:** Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** China

**Manuscript submission date:** 2024-06-05

**Reviewer chosen by:** Yu-Lu Chen

**Reviewer accepted review:** 2024-07-19 05:32

**Reviewer performed review:** 2024-07-23 07:25

**Review time:** 4 Days and 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Novelty of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
<b>Creativity or innovation of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

1. Unfortunately, the image results of the article were not viewed for download in the review system. 2. What is the significance of choosing the GSE140228 data uploaded in 2019, and why was it not statistically analyzed by combining multiple existing data? Is the amount of data used to train and validate the model sufficient to support the conclusions drawn? It is recommended that more data be utilized for analysis. 3. The article specifies that riskscore is the only independent prognostic factor for HCC. Would the AUC value be higher if risk factors, age, gender, grading, and staging were jointly referenced as prognostic factors, and would this be a more accurate assessment? 4. There is duplication in the titles BRGs prognostic model and TCGA official immune typing and BRGs prognostic model evaluates immunotherapy efficacy. 5. Is it sufficiently accurate to classify HCC patients into three subtypes using only the 11 BRGs in the prognostic model? Have the corresponding typing preferences been validated in the clinic? 6. The results of the immune microenvironment and cellular infiltration support the cooperation between B cells and T cells in the suppression of HCC, please elaborate in



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568

**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)

**https://**[www.wjgnet.com](http://www.wjgnet.com)

the discussion the proof that B cells have more value than T cells in HCC treatment.